Search research articles
Contact Us
Filters
Showing results (171-180 of 265) with videos related to
Page
of 27
Sort By:
The New England Journal of Medicine
|
October 22, 2025
Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer
Javier Cortés, Kevin Punie, Carlos Barrios, et al.
Frontiers in Oncology
|
February 6, 2023
Assessing the pathogenicity of <i>BRCA1/2</i> variants of unknown significance: Relevance and challenges for breast cancer precision medicine
Elisa De Paolis, Ida Paris, Bruno Tilocca, et al.
Environmental Research
|
November 29, 2025
Bisphenol A triggers adipocyte dysfunction, thereby fostering triple-negative breast cancer aggressiveness
Anna Citarella, Tanja Milena Autilio, Zein Mersini Besharat, et al.
Journal of Clinical Medicine
|
July 13, 2024
Long-Term Safety of Level II Oncoplastic Surgery after Neoadjuvant Treatment for Locally Advanced Breast Cancer: A 20-Year Experience
Alejandro M Sanchez, Flavia De Lauretis, Angela Bucaro, et al.
Future Oncology (London, England)
|
April 13, 2019
A multicenter real-world study of bevacizumab in heavily pretreated malignant gliomas: clinical benefit is a plausible end point?
Veronica Villani, Alessandra Fabi, Antonio Tanzilli, et al.
Healthcare (Basel, Switzerland)
|
December 30, 2025
A New Model for Bone Health Management in Postmenopausal Early Breast Cancer Patients Undergoing Adjuvant Endocrine Therapy-The Predict & Prevent Project
Stefania Gori, Alessandra Fabi, Rossana Berardi, et al.
Current Oncology (Toronto, Ont.)
|
August 27, 2025
Bone Health and Endocrine Therapy with Ovarian Function Suppression in Premenopausal Early Breast Cancer: A Real-Life Monocenter Experience with Denosumab
Angelachiara Rotondi, Valentina Frescura, Giorgia Arcuri, et al.
International Journal of Cancer
|
November 15, 2019
Dose-dense adjuvant chemotherapy in HER2-positive early breast cancer patients before and after the introduction of trastuzumab: Exploratory analysis of the GIM2 trial
Matteo Lambertini, Francesca Poggio, Marco Bruzzone, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 13, 2024
The journey of patients affected by metastatic hormone receptor-positive/HER2-negative breast cancer from CDK 4/6 inhibitors to second-line treatment: A real-world analysis of 701 patients enrolled in the GIM14/BIOMETA study
Chiara Molinelli, Marco Bruzzone, Eva Blondeaux, et al.
Journal of Experimental & Clinical Cancer Research : CR
|
July 2, 2024
Monitoring changing patterns in HER2 addiction by liquid biopsy in advanced breast cancer patients
Elena Giordani, Matteo Allegretti, Alberto Sinibaldi, et al.
Page
of 27
Search research articles
Search
Showing results (171-180 of 265) with videos related to
Sort By:
Page
of 27
The New England Journal of Medicine
|
October 22, 2025
Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer
Javier Cortés, Kevin Punie, Carlos Barrios, et al.
Frontiers in Oncology
|
February 6, 2023
Assessing the pathogenicity of <i>BRCA1/2</i> variants of unknown significance: Relevance and challenges for breast cancer precision medicine
Elisa De Paolis, Ida Paris, Bruno Tilocca, et al.
Environmental Research
|
November 29, 2025
Bisphenol A triggers adipocyte dysfunction, thereby fostering triple-negative breast cancer aggressiveness
Anna Citarella, Tanja Milena Autilio, Zein Mersini Besharat, et al.
Journal of Clinical Medicine
|
July 13, 2024
Long-Term Safety of Level II Oncoplastic Surgery after Neoadjuvant Treatment for Locally Advanced Breast Cancer: A 20-Year Experience
Alejandro M Sanchez, Flavia De Lauretis, Angela Bucaro, et al.
Future Oncology (London, England)
|
April 13, 2019
A multicenter real-world study of bevacizumab in heavily pretreated malignant gliomas: clinical benefit is a plausible end point?
Veronica Villani, Alessandra Fabi, Antonio Tanzilli, et al.
Healthcare (Basel, Switzerland)
|
December 30, 2025
A New Model for Bone Health Management in Postmenopausal Early Breast Cancer Patients Undergoing Adjuvant Endocrine Therapy-The Predict & Prevent Project
Stefania Gori, Alessandra Fabi, Rossana Berardi, et al.
Current Oncology (Toronto, Ont.)
|
August 27, 2025
Bone Health and Endocrine Therapy with Ovarian Function Suppression in Premenopausal Early Breast Cancer: A Real-Life Monocenter Experience with Denosumab
Angelachiara Rotondi, Valentina Frescura, Giorgia Arcuri, et al.
International Journal of Cancer
|
November 15, 2019
Dose-dense adjuvant chemotherapy in HER2-positive early breast cancer patients before and after the introduction of trastuzumab: Exploratory analysis of the GIM2 trial
Matteo Lambertini, Francesca Poggio, Marco Bruzzone, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 13, 2024
The journey of patients affected by metastatic hormone receptor-positive/HER2-negative breast cancer from CDK 4/6 inhibitors to second-line treatment: A real-world analysis of 701 patients enrolled in the GIM14/BIOMETA study
Chiara Molinelli, Marco Bruzzone, Eva Blondeaux, et al.
Journal of Experimental & Clinical Cancer Research : CR
|
July 2, 2024
Monitoring changing patterns in HER2 addiction by liquid biopsy in advanced breast cancer patients
Elena Giordani, Matteo Allegretti, Alberto Sinibaldi, et al.
Page
of 27